2017 ASH Annual Meeting - Education Program
Description
As the premier event in malignant and non-malignant hematology, the ASH annual meeting provides attendees with an outstanding educational experience that examines the latest clinical advances in hematology and explores the year's most significant scientific discoveries and updates. The videos make this event available for convenient, on-demand viewing.
ASH offers three package options, where you can choose between scientific and educational content, or purchase both at a lower price.
The 2017 ASH Annual Meeting Education Program package includes all of the following sessions:
• General Sessions
• Education Program Sessions
• Special-Interest Sessions
• Spotlight Sessions
• Trainee Simultaneous Didactic Sessions
Access the 2017 ASH Annual Meeting - Complete Meeting for all webcast sessions.
ASH offers three package options, where you can choose between scientific and educational content, or purchase both at a lower price.
The 2017 ASH Annual Meeting Education Program package includes all of the following sessions:
• General Sessions
• Education Program Sessions
• Special-Interest Sessions
• Spotlight Sessions
• Trainee Simultaneous Didactic Sessions
Access the 2017 ASH Annual Meeting - Complete Meeting for all webcast sessions.
Pricing
| Member Type | Price |
|---|---|
| List Price | $350.00 |
| Active, International, Emeritus, and Honorary Members | $225.00 |
| Associate, International Associate, Student, and Resident Members | $100.00 |
Sessions
Education Program
- Acute Lymphocytic Leukemia: New Approaches in Management
- Acute Myeloid Leukemia: How Can We Improve Upon “Standard” Therapy?
- Bone Marrow Failure: Acquired
- Bone Marrow Failure: Inherited
- Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?
- Common Clinical Questions in Cancer-Associated Venous Thromboembolism
- Common Hematologic Consults in Pregnancy
- Congenital and Acquired Neutropenia
- Controversies in Myeloma
- Controversies in Venous Thromboembolism: To Treat or Not to Treat
- Dilemmas in Pediatric Hematologic Malignancy
- Emerging Issues in Clinical Care in Thalassemia
- Evolving Strategies in Aggressive B-Cell Lymphoma
- Hodgkin Lymphoma: New Insights and New Approaches
- Individualizing Therapy in Chronic Lymphocytic Leukemia
- Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making
- It All Starts Here: Disorders of Primary Hemostasis
- Junior Faculty Development Education Session: Grant Funding: How to Get It and How to Keep It Going
- Lessons Learned From Quality Improvement Initiatives in Sickle Cell Disease
- Management of Sickle Cell Disease: Present and Future
- Myelodysplastic Syndromes: Understanding the Current Treatment Landscape
- Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm
- Novel Therapeutics in Myeloma
- Practical Aspects of Acute and Chronic Pain Management in Sickle Cell Disease
- The Challenge of Primary and Secondary Central Nervous System Lymphoma
- The Changing Landscape of Hemophilia Therapy
- The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma
- Therapeutic Apheresis as an Immunomodulatory Tool
- Thrombocytopenia in Hospitalized Patients
- Thrombosis, Devices, and Interventions
- When Graft Versus Tumor Fails: The Biology and Treatment of Relapse After Allogeneic Stem Cell Transplantation
General Sessions
- Announcement of Awards: ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, ASH Public Service Award, and Wallace H. Coulter Award for Lifetime Achievement in Hematology
- Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medal
- ASH-EHA Joint Symposium
- Best of ASH
- E. Donnall Thomas Lecture and Prize
- Ernest Beutler Lecture and Prize
- Ham-Wasserman Lecture
- Presidential Symposium
Special-Interest Sessions
- AML MATTERS: A Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection
- ASH Choosing Wisely® Campaign: 2017 ASH Choosing Wisely Champions
- ASH-FDA Joint Symposium on New Drug Approvals in Acute Lymphoid Leukemia and Non-Hodgkin Lymphoma
- ASH-FDA Joint Symposium on New Drug Approvals in Acute Myeloid Leukemia
- Blood and Beyond: The Art of Perception
- Global Hematology Symposium
- How to Get Published in a Peer-Reviewed Journal
- Quality Conversations on Social Media: Achieving Credibility and Efficiency Together
- Special Education Session on New ASH Clinical Practice Guidelines on Venous Thromboembolism
- Special Session on CAR T Therapy
- Special Session on Systems-Based Hematology
- Special Session on the Hematologic Response to Mass Casualty Radiological Disasters
- Special Symposium on Quality
Spotlight Sessions
- A Sticky Business: New Insights Into Neutrophil Extracellular Traps (NETs) in Physiology and Disease
- Beyond Sequencing: Emerging Tools for Analysis of Multi-Omic Genomic Data in Acquired and Inherited Hematologic Disease
- Debate: Patients With Acquired TTP in Remission Should Be Treated to Prevent Relapse
- Emerging Pathogens from A to Zika and Their Impact on Transfusion Safety
- Getting Patients to Transplant: Myths and Reality
- Identification and Management of Toxicities Induced by Immunotherapies
- The Impact of the Microbiome on the Hematologic System: Thrombosis and Graft-Versus-Host Disease
Trainee Activities and Services
Highlights of ASH
Learn how new clinical research presented at the latest
ASH annual meeting will influence hematology patient care.
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2019 by American Society of Hematology